Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer

被引：0
|
作者：
Jasper, Jacob [1 ]
Kantor, Olga [2 ]
Dorninici, Laura [3 ]
Nakhlis, Faina [4 ]
Ogayo, Esther [5 ]
Nimbkar, Suniti [6 ]
Kurt, Busem Binbogct [5 ]
King, Tari [7 ]
Mittendorf, Elizabeth [7 ]
机构：
[1] Tufts Univ, Medford, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Brigham & Womens Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA
[4] Brigham & Womens Hosp, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Dana Farber Brigham Canc Ctr, South Shore Hosp clin, Boston, MA USA
[7] Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E44
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [21] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [22] Retrospective review of palbociclib (Pal) efficacy and benefit from subsequent treatments following Pal progression in patients (pts) with hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
    Xi, Jing
    Oza, Aabha
    Thomas, Shana
    Naughton, Michael
    Ademuyiwa, Folusa
    Weilbaecher, Katherine N.
    Suresh, Rama
    Bose, Ron
    Cherian, Mathew A.
    Hernandez-Aya, Leonel
    Frith, Ashley
    Peterson, Lindsay L.
    Krishnamurthy, Jairam
    Ma, Cynthia X.
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in Europe.
    Jerusalem, Guy Heinrich Maria
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] HEALTH OUTCOME GAINS AND COSTS OFFSET ASSOCIATED WITH EVEROLIMUS FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE (HR+) HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Taylor, M.
    Lewis, L.
    Vieira, J.
    Ricci, J. F.
    Chandiwana, D.
    Saletan, S.
    Sahmoud, T.
    VALUE IN HEALTH, 2012, 15 (07) : A427 - A427
  • [25] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer
    Alam, Rahat
    Reva, Anna
    Edwards, David G.
    Lege, Bree M.
    Munoz-Arcos, Laura S.
    Reduzzi, Carolina
    Singh, Swarnima
    Hao, Xiaoxin
    Wu, Yi-Hsuan
    Tian, Zeru
    Natalee, Laura M.
    Damle, Gargi
    Demircioglu, Deniz
    Wang, Yixian
    Wu, Ling
    Molteni, Elisabetta
    Hasson, Dan
    Lim, Bora
    Gugala, Zbigniew
    Chipuk, Jerry E.
    Lang, Julie E.
    Sparano, Joseph A.
    Cheng, Chonghui
    Cristofanilli, Massimo
    Xiao, Han
    Zhang, Xiang H. -F.
    Bado, Igor L.
    CANCER DISCOVERY, 2025, 15 (04) : 818 - 837
  • [28] Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
    Wang, Jinhao
    Liu, Yaxin
    Liang, Yuehua
    Zhang, Yue
    Dong, Hang
    Zheng, Tiantian
    Yu, Jianjun
    Du, Pan
    Jia, Shidong
    King, Bonnie L. L.
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo
    Krishnamurthy, Jairam
    Luo, Jingqin
    Ademuyiwa, Foluso
    Suresh, Rama
    Rigden, Caron
    Reardon, Timothy
    Weilbaecher, Katherine
    Frith, Ashley
    Roshal, Anna
    Tandra, Pavan
    Cherian, Mathew
    Summa, Tracy
    Thomas, Shana
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Ma, Cynthia
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
12345